Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines

Mohler, James L.; Armstrong, Andrew J.; Bahnson, Robert R.; Boston, Barry; Busby, J. Erik; D’Amico, Anthony V.; Eastham, James A.; Enke, Charles Arthur; Farrington, Thomas; Higano, Celestia S.; Horwitz, Eric M.; Kantoff, Philip W.; Kawachi, Mark H.; Kuettel, Michael; Lee, Richard J.; MacVicar, Gary R.; Malcolm, Arnold W.; Miller, David C.; Plimack, Elizabeth R.; Pow‐Sang, Julio M.; Roach, Mack; Rohren, Eric M.; Rosenfeld, Stan; Srinivas, Sandy; Strope, Seth A.; Tward, Jonathan D.; Twardowski, Przemyslaw; Walsh, Patrick C.; Ho, Maria Yi; Shead, Dorothy A.

doi:10.6004/jnccn.2012.0114

Cited by 226 publications

(185 citation statements)

References 89 publications

(26 reference statements)

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…26 The use of ADT in combination with radiotherapy has been reported to reduce radiotherapy-associated GU and GI toxicity. 28 All patients in the present study underwent ADT, and their therapeutic outcomes were equivalent to or better than that those achieved by administering high-dose (!80 Gy) radiotherapy, which suggests that the combined use of ADT and IMRT might contribute to improved therapeutic outcomes in prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer

et al. 2015

View full text Add to dashboard Cite

The 5-year distant metastasis-free survival rate was significantly lower for very high-risk patients than for intermediate-and high-risk patients (82.6% vs 99.4% and 96.5%, respectively; P < 0.01). The 5-year biochemical relapse-free survival rates significantly declined with increasing prostate cancer risk (P < 0.01), and were 95.9%, 87.2%, and 73.1% for the intermediate-risk, high-risk and very high-risk patients, respectively. Acute genitourinary and gastrointestinal toxicity grade !3 were not observed in any of the patients. Late grade 3 genitourinary toxicity occurred in 0.3% of patients. Conclusion: Combination androgen-deprivation therapy and 76-Gy intensity-modulated radiation therapy with gold marker implantation offers good therapeutic outcomes with few serious complications in patients with intermediate-and high-risk prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Additionally, for patients at low risk of short-term survival, after docetaxel chemotherapy, both abiraterone acetate and cabazitaxel are available. 26 Because there are no head-to-head clinical trials to compare those drugs, both clinicians and patients are confused when choosing the most suitable agent. As a predictive model, the nomogram can inevitably help make treatment decisions to meet the demand of quality and expectancy of life and to encourage individual counselling and tailored decision making.…”

Section: Discussionmentioning

confidence: 99%

The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer

et al. 2013

View full text Add to dashboard Cite

Based on the results of TAX 327, a nomogram was developed to predict the overall survival of metastatic castration-resistant prostate cancer (mCRPC) after first-line chemotherapy. The nomogram, however, has not been validated in an independent dataset, especially in a series out of clinical trials. Thus, the objective of the current study was to validate the TAX 327 nomogram in a community setting in China. A total of 146 patients with mCRPC who received first-line chemotherapy (docetaxel or mitoxantrone) were identified. Because clinical trials are limited in mainland China, those patients did not receive investigational treatment after the failure of first-line chemotherapy. The predicted overall survival rate was calculated from the TAX 327 nomogram. The validity of the model was assessed with discrimination, calibration and decision curve analysis. The median survival of the cohort was 21 months (docetaxel) and 19 months (mitoxantrone) at last follow-up. The predictive c-index of the TAX 327 nomogram was 0.66 (95% CI: 0.54-0.70). The calibration plot demonstrated that the 2-year survival rate was underestimated by the nomogram. Decision curve analysis showed a net benefit of the nomogram at a threshold probability greater than 30%. In conclusion, the present validation study did not confirm the predictive value of the TAX 327 nomogram in a contemporary community series of men in China, and further studies with a large sample size to develop or validate nomograms for predicting survival and selecting therapies in advanced prostate cancer are necessary.

show abstract

“…Por lo tanto, la detección de lesiones secundarias en pacientes con CP es crucial para decidir la conducta terapéutica, ya que en caso de existir diseminación, generalmente se desestiman las terapias con intención curativa [5][6][7] .…”

unclassified

“…Se prefiere combinar la concentración sérica de APE, puntuación de Gleason en la biopsia de próstata y estadío T clínico como factores predictores del riesgo de lesiones secundarias y estadío final de la enfermedad. Este modelo de análisis resulta superior al compararlo con los parámetros mencionados utilizados en forma independiente, lográndose mayor precisión al estimar el riesgo de diseminación del paciente al momento del diagnóstico [5][6][7]10,[13][14][15][16] .…”

unclassified

¿Es necesario realizar un estudio de etapificación en todos los pacientes con cáncer de próstata?: Experiencia de un centro clínico nacional

M¹,

Calvo

Ibarra

et al. 2017

Rev. méd. Chile

View full text Add to dashboard Cite

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines

Cited by 226 publications

References 89 publications

Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer

Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer

The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer

¿Es necesario realizar un estudio de etapificación en todos los pacientes con cáncer de próstata?: Experiencia de un centro clínico nacional

Contact Info

Product

Resources

About